Financial Data and Key Metrics Changes - In Q4 2025, PYRUKYND generated $20 million in net revenue, an 86% increase year-over-year and a 55% sequential increase from $13 million in Q3 2025 [7][10] - Full-year 2025 revenue for PYRUKND reached $54 million, reflecting robust year-on-year growth [7][10] - The company ended 2025 with approximately $1.2 billion in cash, providing flexibility for future investments [8][11] Business Line Data and Key Metrics Changes - U.S. revenue for PYRUKND in Q4 was $16 million, driven by commercial focus in PK deficiency and favorable growth adjustments [10] - Ex-U.S. revenue was $4 million in Q4, primarily due to inventory stocking ahead of demand [11] - Cost of sales for Q4 was $1.9 million, while R&D expenses were $88.1 million, reflecting an increase associated with advancing the pipeline [11] Market Data and Key Metrics Changes - The U.S. launch of ACTIVASE for thalassemia is underway, with expectations for U.S. PK deficiency revenues in 2026 to be between $45-$50 million [10] - The company anticipates a sequential decline in ex-U.S. revenues into Q1 2026 [11] Company Strategy and Development Direction - The company outlined its 2026 strategic priorities, focusing on executing the launch of Pyrukynd, expanding the PK activation franchise, advancing early-stage pipeline programs, and maintaining financial discipline [5][6] - The company aims to leverage its existing commercial presence in thalassemia and PK deficiency to achieve profitability [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the early market response to ACTIVASE, noting strong engagement from physicians and patients [16] - The company is preparing for a pre-sNDA meeting with the FDA regarding mitapivat for sickle cell disease, which is a critical step in defining the regulatory path [25][44] Other Important Information - The company has completed enrollment in the phase II sickle cell disease trial of tebapivat, with top-line results expected in the second half of 2026 [8][20] - The company is committed to financial discipline, anticipating operating expenses in 2026 to be roughly flat compared to 2025 [12] Q&A Session Summary Question: On the ACTIVASE launch and prescription updates - Management noted that early demand for ACTIVASE is encouraging, with 44 prescriptions written by REMS-certified physicians in the first five weeks of launch [31] - It is expected that prescriptions will grow ahead of revenues due to a 10-12 week conversion time from prescription to treatment initiation [31][32] Question: On sickle cell and tebapivat expectations - Management indicated that the phase II tebapivat trial is a dose-finding trial, and they are excited about the potential hemoglobin response based on previous data [35][36] Question: On payer dynamics and SG&A changes - The payer mix for thalassemia is similar to PK deficiency, with most patients under commercial payers, and initial market access is expected to occur through medical exceptions [93] - SG&A expenses will need to scale up for sickle cell, but the existing infrastructure from PK deficiency and thalassemia will be leveraged [95]

Financial Data and Key Metrics Changes - In Q4 2025, Agios Pharmaceuticals reported net revenue of $20 million from PYRUKYND, an increase of 86% year-over-year and a sequential increase of 55% compared to $13 million in Q3 2025 [10][11] - Full-year 2025 revenue for PYRUKYND reached $54 million, reflecting robust year-on-year growth [7][10] - The company ended Q4 2025 with approximately $1.2 billion in cash, cash equivalents, and marketable securities, providing flexibility for future investments [8][11] Business Line Data and Key Metrics Changes - U.S. revenue for PYRUKYND in Q4 was $16 million, driven by commercial focus in PK deficiency and favorable growth adjustments [10][11] - Ex-U.S. revenue was $4 million in Q4, primarily reflecting inventory stocking ahead of demand from PK deficiency patients in Europe [11] - The company anticipates U.S. PK deficiency revenues to be in the range of $45-$50 million in 2026 [10] Market Data and Key Metrics Changes - The ACTIVASE launch for thalassemia in the U.S. is underway, with strong early demand and 44 prescriptions written by REMS-certified physicians as of January 30 [15][41] - The company has received approval for mitapivat for thalassemia in two regions, with plans for commercialization in Europe and the GCC [18][19] Company Strategy and Development Direction - Agios has outlined its 2026 strategic priorities, focusing on executing the ACTIVASE launch, expanding the PK activation franchise, advancing early-stage pipeline programs, and maintaining financial discipline [5][6] - The company aims to leverage its existing commercial presence in thalassemia and PK deficiency to achieve profitability [12][72] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the early market response to ACTIVASE, noting that physicians view its profile as addressing significant gaps in current treatment options for thalassemia [16][18] - The company anticipates a pivotal year ahead with multiple catalysts, including the pre-sNDA meeting for mitapivat and phase 2 data for tebapivat [25][26] Other Important Information - The company is committed to financial discipline, with operating expenses in 2026 expected to be roughly flat compared to 2025 [12] - Agios is focused on maximizing the launch of ACTIVASE while continuing to advance its pipeline programs [8][25] Q&A Session Summary Question: Can you provide insights on the ACTIVASE launch and prescription updates? - Management noted that early demand is encouraging, with 44 prescriptions written in the first five weeks of launch, and expects prescriptions to grow ahead of revenues due to a 10-12 week conversion time to treatment initiation [31][41] Question: What are the expectations for the phase 2 data in sickle cell disease? - Management indicated that the phase 2 tebapivat trial is a dose-finding study, and they are excited about the potential hemoglobin response based on previous data [35][36] Question: Can you discuss the payer dynamics for ACTIVASE? - The payer mix is similar to PK deficiency, with most patients under commercial payers, and initial access will occur through medical exceptions [93] Question: What is the rationale for higher dosing in lower-risk MDS? - Higher doses are being tested in MDS due to faster metabolism in patients compared to sickle cell disease, which is modeled after healthy volunteers [101] Question: How does the REMS program for thalassemia impact sickle cell disease? - Management believes that the experience gained from the thalassemia REMS program will provide a solid foundation for executing a similar program if needed for sickle cell disease [104]

Financial Data and Key Metrics Changes - In Q4 2025, Agios Pharmaceuticals reported worldwide PYRUKYND revenue of $20 million, an increase of 86% compared to Q4 2024, and a sequential increase of 55% from $13 million in Q3 2025 [9][10] - Full-year 2025 revenue for PYRUKYND reached $54 million, reflecting robust year-on-year growth [5][9] - The company ended Q4 2025 with approximately $1.2 billion in cash, cash equivalents, and marketable securities, providing flexibility for future investments [6][10] Business Line Data and Key Metrics Changes - U.S. fourth quarter revenues for PYRUKYND were $16 million, driven by commercial focus in PK deficiency and favorable growth adjustments [9] - Ex-U.S. revenue was $4 million in Q4, primarily reflecting inventory stocking ahead of demand [10] - Cost of sales for Q4 was $1.9 million, R&D expenses were $88.1 million, and SG&A expenses were $51.6 million, roughly flat year-on-year [10] Market Data and Key Metrics Changes - The ACTIVASE launch for thalassemia in the U.S. is underway, with expectations for U.S. PK deficiency revenues in 2026 to be in the range of $45-$50 million [9][10] - The company anticipates a sequential decline in ex-U.S. revenues into Q1 2026 due to inventory adjustments [10] Company Strategy and Development Direction - The company outlined its 2026 strategic priorities, focusing on executing the ACTIVASE launch, expanding the PK activation franchise, advancing early-stage pipeline programs, and maintaining financial discipline [4][5] - Agios aims to leverage its capital-efficient global commercial model to focus investments on the U.S. market, which presents the most significant revenue opportunity [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the early demand for ACTIVASE, noting strong engagement from physicians and a healthy breadth of early prescribers [14][40] - The company sees a clear path to profitability through its existing commercial presence in thalassemia and PK deficiency, with operating expenses expected to remain flat in 2026 [11][68] Other Important Information - The company received FDA approval for ACTIVASE on December 23, 2025, and the U.S. launch is underway with positive early feedback from physicians [18][19] - Enrollment in the phase II sickle cell disease trial of tebapivat is complete, with top-line results expected in the second half of 2026 [6][20] Q&A Session Summary Question: How does the ACTIVASE launch translate to treatment initiation and revenue recognition? - Management indicated that prescriptions are expected to grow ahead of revenues due to a 10-12 week conversion time from prescription to treatment initiation [29][30] Question: What are the expectations for the phase II data in sickle cell disease? - Management expressed excitement about the trial, noting that it is a dose-finding study aimed at exploring hemoglobin response [34][35] Question: What is the payer mix for ACTIVASE and how does it affect revenue? - The payer mix is similar to PK deficiency, with most patients under commercial payers, and initial market access will occur through medical exceptions [90] Question: What is the rationale for higher dosing in lower-risk MDS compared to sickle cell disease? - Higher doses in MDS are due to faster metabolism in MDS patients, while sickle cell patients metabolize the drug similarly to healthy volunteers [98] Question: What is the expected timeline for profitability? - Management has not provided specific timing but indicated that thalassemia presents a meaningful opportunity for profitability [68][70]